Blood
Articles in this Issue
Functionally high-risk disease is associated with inferior outcomes after chimeric antigen receptor T-cell therapy for relapsed refractory multiple myeloma
Abstract Introduction: Functional high-risk multiple myeloma (FHRMM) is defined through dynamic assessment of disease kinetics after treatme...
Endothelial cell-derived thrombospondin-1 negatively affects hematopoietic function during aging
Abstract The pool of candidates for treatment of hematological malignancies via bone marrow (BM) transplants has greatly expanded due to adv...
Real-world treatment utilization, sequencing, and outcomes in Mantle Cell Lymphoma: Emerging treatment patterns in the United States
Abstract Introduction Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma with poor prognosis and heterogeneous cli...
Efficacy and safety of obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: A reappraisal for low-resource settings
Abstract Background: While chlorambucil has largely been replaced by novel targeted therapies in the treatment of chronic lymphocytic leukem...
Efficacy and safety of duvelisib combined with chidamide as first-line treatment for angioimmunoblastic T-cell lymphoma (AITL)
Abstract Background: Angioimmunoblastic T-cell lymphoma (AITL), an aggressive peripheral T-cell lymphoma (PTCL) subtype, demonstrates limite...
SEPTIN6 mutations in pediatric myelodysplastic syndrome disrupt nuclear actin organization
Abstract Septins are a family of evolutionarily conserved GTP-binding proteins that play critical roles in cytoskeletal organization, cytoki...
Disease characteristics, treatment patterns, and outcomes of AL amyloidosis patients with high-risk FISH cytogenetics
Abstract Background The prognostic relevance of fluorescence in-situ hybridization (FISH) abnormalities is well-established in multiple myel...
Peripheral blood CD34 donor chimerism and flow cytometry for measurable residual disease are complementary assays for predicting relapse of AML after allogeneic transplantation in AML
Abstract Introduction: Relapse remains the leading cause of treatment failure after allogeneic stem cell transplantation...
Orelabrutinib, sintilimab, and temozolomide (OST) in relapsed/refractory primary central nervous system lymphoma
Abstract Introduction Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with a poor prognosis, mainly a...
Cholesterol and lipid-associated transcriptional signature in chronic myeloid leukemia patients with nilotinib-induced hypercholesterolemia
Abstract The efficacy of nilotinib in patients with newly diagnosed Chronic Myeloid Leukemia (CML) has been extensively demonstrated in clin...
Selective targeting of sumoylation disrupts mitochondrial homeostasis via TRAP1 to suppress growth of non-Hodgkin lymphoma (NHL) B-cells
Abstract Introduction: Sumoylation involves the attachment of small ubiquitin-like modifiers (SUMO) proteins to target proteins, thereby mod...
Evaluating the effect of morbid obesity on DVT in patients already on doac therapy: A retrospective analysis
Abstract Background Direct oral anticoagulants (DOACs) are widely used for managing venous thromboembolism (VTE) and atrial fibrillation (AFi...
Short-term hetrombopag for the management of preoperative thrombocytopenia: A multicenter clinical trial
Abstract OBJECTIVE: Preoperative thrombocytopenia critically influences surgical outcomes. Rapidly elevating platelet count to meet perioper...
Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies
Abstract Background Anti-CD19 CAR T-cell therapies have been practice-changing in the management of refractory and relapsed (r/r) B-cell mal...
A case report of ruxolitinib reversing myelofibrosis
Abstract This abstract reports the diagnosis and treatment process of a patient with primary myelofibrosis (PMF). Patient, Huang xx, female,...
Survival outcomes with the use of gemtuzumab-ozogamycin in patients with acute myeloid leukemia receiving intensive chemotherapy stratified by molecular risk category
Abstract Introduction Gemtuzumab-ozogamicin (GO) is a CD33 antibody-drug conjugate that is approved for use in acute myeloid leukemia (AML)...
Efficacy of upfront blinatumomab combined with reduced-intensity chemotherapy for newly diagnosed adult Philadelphia chromosome–negative B-lineage acute lymphoblastic leukemia: Interim analysis of two prospective studies of JSCT ALL/MRD2023 and ALL/MRD2019 in Japan
Abstract Background In adult patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia (Ph– B-ALL), treatment strat...
Low protein expression of Janus kinase 2 (JAK2) is prognostically adverse and independent of mutation status in acute myelogenous leukemia
Abstract INTRODUCTION: Mutations in Janus Kinase (JAK2) occur in <5% of Acute Myelogenous Leukemia (AML) cases and are associated with...
Daclizumab enhances aGVHD prophylaxis by modulating T-cell polarization while preserving the graft-versus-lymphoma effect
Abstract Introduction: Acute graft-versus-host disease (aGvHD) remains a major complication of allogeneic hematopoietic stem cell transplant...
Trial in progress: QUINTESSENTIAL-2—a phase 3 study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide
Abstract Background and Significance: Despite advances in multiple myeloma (MM) treatment, nearly all patients (pts) will relapse, highlight...
Factors associated with the development of second primary malignancies after allogeneic stem cell hematopoietic transplantation. no association with In Vivo T-cell depletion
Abstract Introduction: Second primary malignancies (SPMs) are a well-known complication following allogeneic stem cell hematopoietic transpl...
The efficacy and safety of venetoclax and azacitidine combined with granulocyte-colony stimulating factor in the treatment of Acute Myeloid Leukemia
Abstract Objective This study was designed to evaluate the efficacy and safety of the azacitidine-venetoclax-G-CSF (VAG) combination regimen...
Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data
Abstract Introduction ENRICH compared Ibrutinib + Rituximab (IR) with immunochemotherapy (R-CHEMO) as first line treatments for mantle cell...
Quantification of circulating plasma cells at diagnosis can identify functional high risk multiple myeloma patients
Abstract Background: Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. About 20%...
Phenotype and functional state of endogenous T-cells support T-cell engager therapy in the post-CAR T therapy setting
Abstract INTRODUCTION: Several new therapies have been approved for the treatment of B-cell NHL in the relapsed/refractory setting. CD3xCD20...